Literature DB >> 19151629

Neuropathology of the Mcoln1(-/-) knockout mouse model of mucolipidosis type IV.

Matthew C Micsenyi1, Kostantin Dobrenis, Gloria Stephney, James Pickel, Marie T Vanier, Susan A Slaugenhaupt, Steven U Walkley.   

Abstract

The recently developed Mcoln1(-/-) knockout mouse provides a novel model for analyzing mucolipin 1 function and mucolipidosis type IV disease. Here we characterize the neuropathology of Mcoln1(-/-) mouse at the end stage. Evidence of ganglioside accumulation, including increases in GM2, GM3, and GD3 and redistribution of GM1, was found throughout the central nervous system (CNS) independent of significant cholesterol accumulation. Unexpectedly, colocalization studies using immunofluorescence confocal microscopy revealed that GM1 and GM2 were present in separate vesicles within individual neurons. While GM2 was significantly colocalized with LAMP2, consistent with late-endosomal/lysosomal processing, some GM2-immunoreactivity occurred in LAMP2-negative sites, suggesting involvement of other vesicular systems. P62/Sequestosome 1 (P62/SQSTM1) inclusions were also identified in the CNS of the Mcoln1(-/-) mouse, suggesting deficiencies in protein degradation. Glial cell activation was increased in brain, and there was evidence of reduced myelination in cerebral and cerebellar white matter tracts. Autofluorescent material accumulated throughout the brains of the knockout mice. Finally, axonal spheroids were prevalent in white matter tracts and Purkinje cell axons. This neuropathological characterization of the Mcoln1(-/-) mouse provides an important step in understanding how mucolipin 1 loss of function affects the CNS and contributes to mucolipidosis type IV disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151629      PMCID: PMC4232971          DOI: 10.1097/NEN.0b013e3181942cf0

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  47 in total

1.  Elevated lysosomal pH in Mucolipidosis type IV cells.

Authors:  G Bach; C S Chen; R E Pagano
Journal:  Clin Chim Acta       Date:  1999-02       Impact factor: 3.786

2.  Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies.

Authors:  E Kuusisto; A Salminen; I Alafuzoff
Journal:  Neuroreport       Date:  2001-07-20       Impact factor: 1.837

3.  Mucolipidosis type IV: abnormal transport of lipids to lysosomes.

Authors:  R Bargal; G Bach
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

Review 4.  Pathobiology of neuronal storage disease.

Authors:  S U Walkley
Journal:  Int Rev Neurobiol       Date:  1988       Impact factor: 3.230

Review 5.  TRPML and lysosomal function.

Authors:  David A Zeevi; Ayala Frumkin; Gideon Bach
Journal:  Biochim Biophys Acta       Date:  2007-01-19

6.  Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV.

Authors:  Bhuvarahamurthy Venugopal; Marsha F Browning; Cyntia Curcio-Morelli; Andrea Varro; Norman Michaud; Nanda Nanthakumar; Steven U Walkley; James Pickel; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

7.  Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis.

Authors:  Sabrina Jabs; Arne Quitsch; Reijo Käkelä; Bettina Koch; Jaana Tyynelä; Helmut Brade; Markus Glatzel; Steven Walkley; Paul Saftig; Marie T Vanier; Thomas Braulke
Journal:  J Neurochem       Date:  2008-05-21       Impact factor: 5.372

8.  Mucolipidosis IV. Clinical, ultrastructural, histochemical, and chemical studies of a case, including a brain biopsy.

Authors:  I Tellez-Nagel; I Rapin; T Iwamoto; A B Johnson; W T Norton; H Nitowsky
Journal:  Arch Neurol       Date:  1976-12

9.  p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.

Authors:  Serhiy Pankiv; Terje Høyvarde Clausen; Trond Lamark; Andreas Brech; Jack-Ansgar Bruun; Heidi Outzen; Aud Øvervatn; Geir Bjørkøy; Terje Johansen
Journal:  J Biol Chem       Date:  2007-06-19       Impact factor: 5.157

10.  The neurogenetics of mucolipidosis type IV.

Authors:  G Altarescu; M Sun; D F Moore; J A Smith; E A Wiggs; B I Solomon; N J Patronas; K P Frei; S Gupta; C R Kaneski; O W Quarrell; S A Slaugenhaupt; E Goldin; R Schiffmann
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

View more
  58 in total

1.  Elevation of GM2 ganglioside during ethanol-induced apoptotic neurodegeneration in the developing mouse brain.

Authors:  Mitsuo Saito; Goutam Chakraborty; Relish Shah; Rui-Fen Mao; Asok Kumar; Dun-Sheng Yang; Kostantin Dobrenis; Mariko Saito
Journal:  J Neurochem       Date:  2012-03-20       Impact factor: 5.372

2.  A novel homozygous MCOLN1 double mutant allele leading to TRP channel domain ablation underlies Mucolipidosis IV in an Italian Child.

Authors:  Marisol Mirabelli-Badenier; Mariasavina Severino; Barbara Tappino; Domenico Tortora; Francesca Camia; Clelia Zanaboni; Fabia Brera; Enrico Priolo; Andrea Rossi; Roberta Biancheri; Maja Di Rocco; Mirella Filocamo
Journal:  Metab Brain Dis       Date:  2014-08-26       Impact factor: 3.584

3.  N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.

Authors:  Lauren C Boudewyn; Jakub Sikora; Ladislav Kuchar; Jana Ledvinova; Yulia Grishchuk; Shirley L Wang; Kostantin Dobrenis; Steven U Walkley
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

4.  Suppression of the motor deficit in a mucolipidosis type IV mouse model by bone marrow transplantation.

Authors:  Marquis T Walker; Craig Montell
Journal:  Hum Mol Genet       Date:  2016-06-07       Impact factor: 6.150

Review 5.  Role of TRP channels in the regulation of the endosomal pathway.

Authors:  Ken Abe; Rosa Puertollano
Journal:  Physiology (Bethesda)       Date:  2011-02

Review 6.  Transient receptor potential channelopathies.

Authors:  Bernd Nilius; Grzegorz Owsianik
Journal:  Pflugers Arch       Date:  2010-02-04       Impact factor: 3.657

7.  Ganglioside accumulation in activated glia in the developing brain: comparison between WT and GalNAcT KO mice.

Authors:  Mariko Saito; Gusheng Wu; Maria Hui; Kurt Masiello; Kostantin Dobrenis; Robert W Ledeen; Mitsuo Saito
Journal:  J Lipid Res       Date:  2015-06-10       Impact factor: 5.922

8.  Lysosomal membrane permeability stimulates protein aggregate formation in neurons of a lysosomal disease.

Authors:  Matthew C Micsenyi; Jakub Sikora; Gloria Stephney; Kostantin Dobrenis; Steven U Walkley
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

Review 9.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.